Literature DB >> 17211859

Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.

A Heather Eliassen1, Shelley S Tworoger, Susan E Hankinson.   

Abstract

Many reproductive factors are associated with breast cancer risk, potentially through a hormonal pathway. The peptide hormone prolactin is essential in mammary development and lactation and may be a link between risk factors and breast cancer. While higher prolactin levels are associated with increased breast cancer risk, few determinants of prolactin levels are known. We conducted a cross-sectional analysis among 1,089 premenopausal and 1,311 postmenopausal women within the Nurses' Health Study (NHS) and the NHS II to examine the associations of reproductive factors, benign breast disease and family history of breast cancer with plasma prolactin levels. Parous women had significantly lower prolactin levels than nulliparous women (parous vs. nulliparous multivariate-adjusted geometric means = 14.1 ng/mL vs. 16.6 ng/mL, p<0.001 for premenopausal and 9.1 vs. 10.1, p=0.04 for postmenopausal women), although levels did not decrease with increasing number of children for either premenopausal (p-trend = 0.23) or postmenopausal (p-trend = 0.07) parous women. Age at first birth was not associated with prolactin levels. The reduction in prolactin levels among parous premenopausal women appeared to attenuate with increasing time since first birth, but the trend was not statistically significant (p-trend = 0.12). Age at menarche, duration of lactation and benign breast disease were not associated with prolactin levels. Family history of breast cancer was associated with significantly higher prolactin levels when compared with no family history among premenopausal (15.9 ng/mL vs. 14.3 ng/mL, p=0.04) but not postmenopausal (p=0.73) women. In conclusion, the associations of parity and family history with breast cancer risk may be mediated, at least in part, by prolactin levels. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211859     DOI: 10.1002/ijc.22482

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Authors:  Feng Fang; Jiamao Zheng; Traci L Galbaugh; Alyson A Fiorillo; Elizabeth E Hjort; Xianke Zeng; Charles V Clevenger
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

2.  Determinants of prolactin in postmenopausal Chinese women in Singapore.

Authors:  Tiffany A Katz; Anna H Wu; Frank Z Stanczyk; Renwei Wang; Woon-Puay Koh; Jian-Min Yuan; Steffi Oesterreich; Lesley M Butler
Journal:  Cancer Causes Control       Date:  2017-11-09       Impact factor: 2.506

3.  The association of reproductive and lifestyle factors with a score of multiple endogenous hormones.

Authors:  Amy L Shafrir; Xuehong Zhang; Elizabeth M Poole; Susan E Hankinson; Shelley S Tworoger
Journal:  Horm Cancer       Date:  2014-07-22       Impact factor: 3.869

4.  Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation.

Authors:  Mandar V Kulkarni; M Cristina Tettamanzi; James W Murphy; Camille Keeler; David G Myszka; Naomi E Chayen; Elias J Lolis; Michael E Hodsdon
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

5.  Energy balance, early life body size, and plasma prolactin levels in postmenopausal women.

Authors:  Xuefen Su; Susan E Hankinson; Charles V Clevenger; A Heather Eliassen; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-14       Impact factor: 2.506

6.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

7.  Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer.

Authors:  Stefan K Siwko; Jie Dong; Michael T Lewis; Hao Liu; Susan G Hilsenbeck; Yi Li
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

8.  Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Megan S Rice; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-14       Impact factor: 4.254

9.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

Review 10.  Secondary effects of antipsychotics: women at greater risk than men.

Authors:  Mary V Seeman
Journal:  Schizophr Bull       Date:  2008-04-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.